# NVE Corp: Form 10-Q for the period ended Sep 30, 2017

- Company: [NVE Corp](/companies/nvec.md) (CIK 724910)
- Form: 10-Q
- Filed: 2017-10-18
- Accepted by EDGAR: Oct 18, 2017, 16:25 ET
- Period: 2017-09-30
- Accession: 0000724910-17-000039
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/724910/000072491017000039/NVE_Q2_FY2018_10Q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/724910/000072491017000039/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2017-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2017-07-01 to 2017-09-30 | $7.0m | us-gaap:Revenues |
| Revenue | 6 months, 2017-04-01 to 2017-09-30 | $14.6m | us-gaap:Revenues |
| Cost of revenue | 3 months, 2017-07-01 to 2017-09-30 | $1.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2017-04-01 to 2017-09-30 | $3.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2017-07-01 to 2017-09-30 | $5.6m | us-gaap:GrossProfit |
| Gross profit | 6 months, 2017-04-01 to 2017-09-30 | $11.5m | us-gaap:GrossProfit |
| Research and development | 3 months, 2017-07-01 to 2017-09-30 | $1.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2017-04-01 to 2017-09-30 | $1.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2017-07-01 to 2017-09-30 | $348.4k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2017-04-01 to 2017-09-30 | $747.7k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2017-07-01 to 2017-09-30 | $4.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2017-04-01 to 2017-09-30 | $8.8m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2017-07-01 to 2017-09-30 | $1.5m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2017-04-01 to 2017-09-30 | $3.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2017-07-01 to 2017-09-30 | $3.2m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2017-04-01 to 2017-09-30 | $6.5m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2017-07-01 to 2017-09-30 | $0.65 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2017-04-01 to 2017-09-30 | $1.33 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2017-07-01 to 2017-09-30 | $0.65 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2017-04-01 to 2017-09-30 | $1.33 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2017-07-01 to 2017-09-30 | 4,845,632 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2017-04-01 to 2017-09-30 | 4,845,907 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2017-04-01 to 2017-09-30 | $7.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2017-04-01 to 2017-09-30 | $526.4k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 6 months, 2017-04-01 to 2017-09-30 | $9.7m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2017-09-30 | $5.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2017-09-30 | $28.7m | us-gaap:AssetsCurrent |
| Total assets | at 2017-09-30 | $90.4m | us-gaap:Assets |
| Current liabilities | at 2017-09-30 | $830.5k | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2017-09-30 | $89.6m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 9,548 characters.

### Forward-looking statements

Some of the statements made in this Report or in the documents incorporated by reference in this Report and in other materials filed or to be filed by us with the Securities and Exchange Commission (“SEC”) as well as information included in verbal or written statements made by us constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to the safe harbor provisions of the reform act. Forward-looking statements may be identified by the use of the terminology such as may, will, expect, anticipate, intend, believe, estimate, should, or continue, or the negatives of these terms or other variations on these words or comparable terminology. To the extent that this Report contains forward-looking statements regarding the financial condition, operating results, business prospects or any other aspect of NVE, you should be aware that our actual financial condition, operating results and business performance may differ materially from that projected or estimated by us in the forward-looking statements. We have attempted to identify, in context, some of the factors that we currently believe may cause actual future experience and results to differ from their current expectations. These differences may be caused by a variety of factors, including but not limited to our reliance on several large customers for a significant percentage of revenue, uncertainties related to the economic environments in the industries we serve, uncertainties related to future contract research and development revenue, uncertainties related to future stock repurchases and dividend payments, and other specific risks that may be alluded to in this Report or in the documents incorporated by reference in this Report.

Further information regarding our risks and uncertainties are contained in Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended March 31, 2017.

### General

NVE Corporation, referred to as NVE, we, us, or our, develops and sells devices that use spintronics, a nanotechnology that relies on electron spin rather than electron charge to acquire, store and transmit information. We manufacture high-performance spintronic products including sensors and couplers that are used to acquire and transmit data. We have also licensed our spintronic magnetoresistive random access memory technology, commonly known as MRAM.

### Critical accounting policies

A description of our critical accounting policies is provided in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended March 31, 2017. As of September 30, 2017 our critical accounting policies and estimates continued to include investment valuation, inventory valuation, and deferred tax assets estimation.

### Quarter ended September 30, 2017 compared to quarter ended September 30, 2016

The table shown below summarizes the percentage of revenue and quarter-to-quarter changes for various items:

*Revenue*

| 2017 | Percentage of Revenue Quarter Ended Sept. 30 | 2016 | Quarter- to-Quarter Change |
| --- | ---: | ---: | ---: |
| Product sales | 91.3% | 93.3% | (6.3)% |
| Contract research and development | 8.7% | 6.7% | 24.8% |
| Total revenue | 100.0% | 100.0% | (4.2)% |
| Cost of sales | 19.3% | 23.8% | (22.3)% |
| Gross profit | 80.7% | 76.2% | 1.5% |
| Expenses |  |  |  |
| Selling, general, and administrative | 5.0% | 4.7% | 1.4% |
| Research and development | 14.8% | 10.6% | 34.1% |
| Total expenses | 19.8% | 15.3% | 24.0% |
| Income from operations | 60.9% | 60.9% | (4.2)% |
| Interest income | 5.6% | 5.9% | (10.0)% |
| Income before taxes | 66.5% | 66.8% | (4.7)% |
| Provision for income taxes | 21.3% | 21.5% | (5.4)% |
| Net income | 45.2% | 45.3% | (4.4)% |

Total revenue for the quarter ended September 30, 2017 (the second quarter of fiscal 2018) decreased 4% compared to the quarter ended September 30, 2016 (the second quarter of fiscal 2017). The decrease was due to a 6% decrease in product sales, partially offset by a 25% increase in contract research and development revenue.

The decrease in product sales from the prior-year quarter was primarily due to decreased purchases by existing customers. The increase in contract research and development revenue for the second quarter of fiscal 2018 was due to new contracts.

Gross profit margin increased to 81% of revenue for the second quarter of fiscal 2018 compared to 76% for the second quarter of fiscal 2017, due to increased gross profit margins on both product sales and contract research and development.

Total expenses increased 24% for the second quarter of fiscal 2018 compared to the second quarter of fiscal 2017, due to a 1% increase in selling, general, and administrative expense and a 34% increase in research and development expense. The increase in research and development expense was due to increased new product development activities.

Interest income for the second quarter of fiscal 2018 decreased 10% due to a decrease in marketable securities and a decrease in the average interest rates on those securities.

The 4% decrease in net income in the second quarter of fiscal 2018 compared to the prior-year quarter was primarily due to decreased product sales, increased research and development expense, and decreased interest income, partially offset by increased contract research and development revenue and increased gross profit margin.

### Six months ended September 30, 2017 compared to six months ended September 30, 2016

The table shown below summarizes the percentage of revenue and period-to-period changes for various items:

*Revenue*

| 2017 | Percentage of Revenue Six Months Ended Sept. 30 | 2016 | Period- to-Period Change |
| --- | ---: | ---: | ---: |
| Product sales | 90.9% | 90.4% | 4.8% |
| Contract research and development | 9.1% | 9.6% | (0.8)% |
| Total revenue | 100.0% | 100.0% | 4.2% |
| Cost of sales | 21.6% | 22.3% | 0.8% |
| Gross profit | 78.4% | 77.7% | 5.2% |
| Expenses |  |  |  |
| Selling, general, and administrative | 5.1% | 5.2% | 1.9% |
| Research and development | 13.3% | 10.9% | 26.8% |
| Total expenses | 18.4% | 16.1% | 18.8% |
| Income from operations | 60.0% | 61.6% | 1.7% |
| Interest income | 5.2% | 6.2% | (13.7)% |
| Income before taxes | 65.2% | 67.8% | 0.3% |
| Provision for income taxes | 21.0% | 21.8% | 0.1% |
| Net income | 44.2% | 46.0% | 0.3% |

Total revenue for the six months ended September 30, 2017 increased 4% compared to the six months ended September 30, 2016. The increase was primarily due to a 5% increase in product sales.

The increase in product sales from the prior-year period was due to increased purchase volumes by existing customers and new customers.

Total expenses increased 19% for the first six months of fiscal 2018 compared to the first six months of fiscal 2017, due to a 2% increase in selling, general, and administrative expense and a 27% increase in research and development expense. The increase in research and development expense was due to increased new product development activities.

Interest income for the first six months of fiscal 2018 decreased 14% due to a decrease in marketable securities and a decrease in the average interest rates on those securities.

Net income in the first six months of fiscal 2018 was approximately the same as the prior-year period, primarily because increased product sales were approximately offset by increased expenses and decreased interest income.

### Liquidity and capital resources

### Overview

Cash and cash equivalents were $5,108,313 as of September 30, 2017 compared to $8,199,364 as of March 31, 2017. The $3,091,051 decrease in cash and cash equivalents during the six months ended September 30, 2017 was due to $9,682,020 cash used in financing activities for dividends, $725,337 cash used in investing activities, partially offset by $7,316,306 in net cash provided by operating activities. We currently believe our working capital and cash generated from operations will be adequate for our needs at least for the next 12 months.

### Operating Activities

Accounts receivable as of September 30, 2017 decreased $777,184 compared to March 31, 2017, primarily due to the timing of sales to and payments from certain customers.

### Investing Activities

Cash used in investing activities in the six months ended September 30, 2017 was due to $12,138,960 in purchases of marketable securities and $526,377 in purchases of fixed assets, partially offset by $11,940,000 of marketable security maturities.

### Financing Activities

Cash used in financing activities in the first six months of fiscal 2018 was due to $9,682,020 of cash dividends paid to shareholders. In addition to dividends paid in the first six months of fiscal 2018, on October 18, 2017 we announced that our Board had declared a cash quarterly dividend of $1.00 per share of common stock, or $4,841,010 based on shares outstanding as of October 13, 2017, to be paid November 30, 2017. We plan to fund dividends through cash provided by operating activities and proceeds from maturities and sales of marketable securities. All future dividends will be subject to Board approval and subject to the company’s results of operations, cash and marketable security balances, estimates of future cash requirements, and other factors the Board may deem relevant. Furthermore, dividends may be modified or discontinued at any time without notice.

## Market risk

As filed, 1,221 characters.

As discussed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017, we are exposed to financial market risks, primarily marketable securities and, to a lesser extent, changes in currency exchange rates.

### Marketable Securities

The primary objective of our investment activities is to preserve principal while at the same time maximizing after-tax yields without significantly increasing risk. To achieve this objective, we maintain our portfolio of cash equivalents and marketable securities in securities including municipal obligations, corporate obligations, and money market funds. Short-term and long-term marketable securities are generally classified as available-for-sale and consequently are recorded on the balance sheet at fair value with unrealized gains or losses reported as a separate component of accumulated other comprehensive income or loss, net of estimated tax. Our marketable securities as of September 30, 2017 had remaining maturities between one and 247 weeks. Marketable securities had a market value of $76,544,498 as of September 30, 2017, representing approximately 85% of our total assets. We have not used derivative financial instruments in our investment portfolio.

## Controls and procedures

As filed, 1,341 characters.

### Disclosure Controls and Procedures

Management, with the participation of the Chief Executive Officer and Chief Financial Officer, has performed an evaluation of our disclosure controls and procedures that are defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”) as of the end of the period covered by this Report. This evaluation included consideration of the controls, processes, and procedures that are designed to ensure that information required to be disclosed by us in the reports we file under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2017, our disclosure controls and procedures were effective.

### Changes in Internal Controls

During the quarter ended September 30, 2017, there was no change in our internal control over financial reporting that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 143 characters.

There have been no material changes from the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2017.

Filed Oct 18, 2017.
Source: SEC EDGAR, the filing index for accession 0000724910-17-000039. Last ingested by Listed: Nov 5, 2026, 19:10 ET. No prices; not investment advice.
